TopoTarget and Lundbeck sign agreement for siramesine - a new and promising mechanism in cancer therapy

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com

TopoTarget and Lundbeck sign agreement for siramesine - a new and promising
mechanism in cancer therapy 


Copenhagen, Denmark - 4 October 2007 - TopoTarget and Lundbeck today announced
an agreement for the development of siramesine for the treatment of cancer. 

Siramesine has shown strong results in preclinical studies carried out by the
Danish Cancer Society. The studies showed that siramesine kills cancer cells
via a new and promising mechanism. Siramesine was originally developed by
Lundbeck for the treatment of diseases of the central nervous system (CNS), and
TopoTarget now intends to initiate studies with the compound in cancer therapy. 

“With this agreement we obtain the rights to develop siramesine for the
treatment of cancer. Lundbeck has completed fundamental development activities
by bringing the compound through Phase I studies. We now wish to investigate
siramesine in our discovery models to look into its Phase II development
potential,” said Peter Buhl Jensen, CEO of TopoTarget. “Siramesine complements
TopoTarget's existing pipeline as the compound provides a new mechanism of
action and is facing Phase II development, an area where TopoTarget has
considerable development competences,” added Peter Buhl Jensen. 

Applying its special expertise and in-house discovery models, TopoTarget seeks
to identify the best Phase II development opportunities for the benefit of
cancer patients. The successful completion of Phase II may lead to yet another
partner entering the collaboration with a view to further clinical and
commercial development. Any future income will be evenly divided between
TopoTarget and Lundbeck. 

Siramesine binds to a special sub-type of sigma receptor (σ 2). Siramesine has
previously been investigated in Phase I and Phase IIa studies as a CNS-active
compound for the treatment of anxiety, demonstrating a favourable tolerability
profile. 

Novel studies conducted under the supervision of professor Marja Jäättelä of
the Danish Cancer Society showed that siramesine induces caspase-independent
apoptosis (cell killing) in cancer cells and is effective in pre-clinical
cancer models, both as monotherapy and in combination with currently marketed
anti-cancer drugs. 

The siramesine agreement does not change TopoTarget's full-year financial
guidance for 2007. 


TopoTarget A/S	
For further information, please contact:

Dr. Peter Buhl Jensen			Telephone	+45 39 17 83 41
Chief Executive Officer			Mobile		+45 21 60 89 22

Tim Corcoran				Telephone	+44 1235 443 713
Chief Operating Officer			Mobile		+44 787 656 1027

Ulla Hald Buhl				Mobile		+45 21 70 10 49
Director of IR and Communications	


Background information

About TopoTarget
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with
subsidiaries in US, Switzerland, Germany and the UK, dedicated to finding
''Answers for cancer'' and developing improved cancer therapies. TopoTarget is
founded and run by clinical cancer specialists and combines years of hands-on
clinical experience with in-depth understanding of the molecular mechanisms of
cancer. Focus lies on highly predictive cancer models and key cancer targets
(including HDACi, NAD+,  mTOR, FASligand and topoisomerase II inhibitors) and a
strong development foundation has been built. TopoTarget has a broad portfolio
of small molecule pre-clinical drug candidates and eight drugs (both small
molecules and protein based) are in clinical development, including both novel
anti-cancer therapeutics and new cancer indications for existing drugs.
Savene™/Totect™ was approved by EMEA in 2006 and the FDA in 2007 and is
TopoTarget's first product on the market. For more information, please refer to
www.topotarget.com. 

TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements.  TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks;  uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.